Exclusively focused on translational aspects of drug delivery, this journal provides a unique forum for publication of high-quality research.
Drug Delivery and Translational Research publishes research focused on such topics as designing and developing novel drug delivery systems, with a focus on their application to disease conditions; preclinical and clinical data related to drug delivery systems; short-term and long-term biocompatibility of drug delivery systems, host response; biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering; image-guided drug therapy; nanomedicine; devices for drug delivery and drug/device combination products.
In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to activities of the Controlled Release Society.
Drug Delivery and Translational Research publishes six issues a year.
- Accepted by ISI in SCIE, Biosis Previews and Biological Abstracts
- Explores the effect in different disease conditions of rationally developed, effective delivery systems
- Focuses on high-quality research on the development of novel drug delivery systems
- Presents full-length papers, communications, and reviews, editorials and more
- Maria Jose Alonso
- Publishing model
- Hybrid (Transformative Journal). Learn about publishing Open Access with us
- 2.664 (2019)
- Impact factor
- 3.041 (2019)
- Five year impact factor
- 41 days
- Submission to first decision
- 137 days
- Submission to acceptance
- 196,391 (2020)
Segmented intravaginal ring for the combination delivery of hydroxychloroquine and anti-CCR5 siRNA nanoparticles as a potential strategy for preventing HIV infection
Authors (first, second and last of 4)
Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model
Authors (first, second and last of 14)
γ-Cyclodextrin metal–organic framework as a carrier to deliver triptolide for the treatment of hepatocellular carcinoma
Authors (first, second and last of 8)
Preparation of olmesartan medoxomil solid dispersion with sustained release performance by mechanochemical technology
Authors (first, second and last of 6)
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
In this Inspirational Note, Drs. Lara Milane and Mansoor Amiji share their insights and reflections on the impact of the recently approved SARS-CoV-2 mRNA vaccines on the present and future of translational nanomedicines.
Congratulations to the authors of Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B for winning the DDTR Best Paper of the Year Award for 2020.
Summary: Treatment of the neurological manifestations of lysosomal storage diseases remains an unmet medical need. BMN 250 is being developed as an enzyme replacement therapy administered directly into the brain ventricles via the intracerebroventricular (ICV) route for treating Sanfilippo type B. Patients with this rare neurological disease have deficient lysosomal alpha-N-acetylglucosaminidase (NAGLU) enzyme activity. Unlike the ICV route that readily provides biodistribution of therapy to target cells, we show in wild-type and disease animal models that intravenously-administered enzyme does not reach the target neuronal cells. The limited pharmacological response following intravenous administration is likely attributed to the clearance of substrate in endothelial cells that restrict biodistribution to target cells in the brain. Representative staining from superficial medulla oblongata from cynomolgus monkey received BMN 250 via the IV route shows that all NAGLU staining is co-localized with CD31-positive endothelial cells, indicating that IV administered NAGLU does not reach the target neurons. In contrast, NAGLU co-localizes with the neurons following ICV administration.
Societies, partners and affiliations
About this journal
- Electronic ISSN
- Print ISSN
- Abstracted and indexed in
- Chemical Abstracts Service (CAS)
- EBSCO Discovery Service
- Google Scholar
- Institute of Scientific and Technical Information of China
- Japanese Science and Technology Agency (JST)
- Journal Citation Reports/Science Edition
- OCLC WorldCat Discovery Service
- ProQuest-ExLibris Primo
- ProQuest-ExLibris Summon
- Science Citation Index Expanded (SciSearch)
- TD Net Discovery Service
- UGC-CARE List (India)